Characterization of T and B cell repertoire diversity in patients with RAG deficiency. by Lee, YN et al.
Characterization of T and B cell repertoire diversity in patients 
with RAG deficiency*
Yu Nee Lee, Ph.D.1,2, Francesco Frugoni, Ph.D.1, Kerry Dobbs, B.S.3, Irit Tirosh, M.D.1, 
Likun Du, Ph.D.1, Francesca A. Ververs, M.D.1, Heng Ru, Ph.D.4, Lisa Ott de Bruin, M.D.1, 
Mehdi Adeli, M.D.5, Jacob H. Bleesing, M.D., Ph.D.6, David Buchbinder, M.D.7, Manish J. 
Butte, M.D., Ph.D.8, Caterina Cancrini, M.D.9, Karin Chen, M.D.10, Sharon Choo, M.D.11, 
Reem A. Elfeky, M.D.12, Andrea Finocchi, M.D.9, Ramsay L. Fuleihan, M.D.13, Andrew R. 
Gennery, M.D.14, Dalia H. El-Ghoneimy, M.D.12, Lauren A. Henderson, M.D.1, Waleed Al-
Herz, M.D.15, Elham Hossny, M.D. Ph.D.12, Robert P. Nelson, M.D16, Sung-Yun Pai, M.D.17, 
Niraj C. Patel, M.D.18, Shereen M. Reda, M.D. Ph.D.12, Pere Soler-Palacin, M.D.19, Raz 
Somech, M.D., Ph.D.2, aolo Palma, M.D.9, Hao Wu, Ph.D.4, Silvia Giliani, Ph.D.20, Jolan E. 
Walter, M.D., Ph.D.1,21, and Luigi D. Notarangelo, M.D.3,*
1Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, 
USA.
2Pediatric Department A and the Immunology Service, "Edmond and Lily Safra" Children's 
Hospital, Jeffrey Modell Foundation Center, Sheba Medical Center, Tel Hashomer, Sackler 
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
3Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, Bethesda, MD, USA.
4Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 
Boston, MA 02115, USA; Program in Cellular and Molecular Medicine, Boston Children's 
Hospital, Boston, MA 02115, USA.
5Pediatrics Department, Weill Cornell Medical College, Hamad Medical Corporation, Doha, Qatar.
6Division of Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 
USA.
7Division of Hematology, Children’s Hospital Orange County, Orange County, CA, USA.
*This manuscript has been accepted for publication in Science Immunology. This version has not undergone fine editing. Please refer 
to the complete version of record at http://immunology.sciencemag.org. The manuscript may not be reproduced or used in any manner 
that does not fall within the fair use provisions of the Copyright Act without the prior, written permission of AAAS.
*Address correspondence to: L.D.N. luigi.notarangelo2@nih.gov, Laboratory of Host Defenses, NIAID, NIH, 10 Center Drive, MSC 
1456, Building 10 CRC, Room 5-3950, Bethesda, MD 20892. 
Author contributions: YNL and LDN designed the study, supervised analysis of the data and wrote the manuscript; YNL, FF, KD, 
IT, LD, FV, HR, and HW performed the experiments and analyzed the data; YNL performed statistical analysis; MA, JHB, DB, MB, 
CC, KC, SC, RAEF, AF, RLF, ARG, DHEG, LAH, WAH, EH, RPN, SYP, NCP, SMR, PSP, RS, PP, JEW, SG and LDN provided 
valuable samples and gathered the data. HR and HW analyzed the potential effects of the mutations on the RAG1/RAG2 
heterotetrameric structure. LODB helped with the manuscript writing.
Competing interests: The authors declare no competing interests.
Data and material availability: Please see Supplementary Excel file for the IGH and TRB sequences.
HHS Public Access
Author manuscript
Sci Immunol. Author manuscript; available in PMC 2017 September 06.
Published in final edited form as:
Sci Immunol. 2016 December 16; 1(6): . doi:10.1126/sciimmunol.aah6109.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
8Department of Pediatrics, Division of Allergy, Immunology, Rheumatology, Stanford University, 
Stanford, California, USA.
9DPUO, University Department of Pediatrics, Bambino Gesù Children’s Hospital and University of 
Tor Vergata School of Medicine, Rome, Italy.
10Division of Allergy and Immunology, Department of Pediatrics, University of Utah School of 
Medicine, Salt Lake City, UT, USA.
11Department of Immunology, The Royal Children's Hospital, Melbourne, Australia.
12Department of Pediatric Allergy and Immunology, Children’s Hospital, Faculty of Medicine, Ain 
Shams University, Cairo, Egypt.
13Division of Allergy and Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, 
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
14Department of Paediatric Immunology, Great North Children’s Hospital, United Kingdom, and 
Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK.
15Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait.
16Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN, 
USA.
17Division of Hematology-Oncology, Boston Children’s Hospital, Boston, MA, USA.
18Department of Pediatrics, Division of Infectious Disease and Immunology, Levine Children's 
Hospital, Carolinas Medical Center, Charlotte, NC, USA.
19Paediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron University Hospital, 
Barcelona, Spain.
20A. Nocivelli Institute for Molecular Medicine, Department of Molecular and Translational 
Medicine, University of Brescia, and the Section of Medical Genetics, Department of Pathology 
Spedali Civili, Brescia, Italy.
21Division of Pediatric Allergy/Immunology, University of South Florida, and Johns Hopkins All 
Children’s Hospital, St. Petersburg, FL, USA.
Abstract
Recombination Activating Genes 1 and 2 (RAG1 and RAG2) play a critical role in T and B cell 
development by initiating the recombination process that controls expression of T cell receptor 
(TCR) and immunoglobulin genes. Mutations in the RAG1 and RAG2 genes in humans cause a 
broad spectrum of phenotypes, including severe combined immune deficiency (SCID) with lack of 
T and B cells, Omenn syndrome, leaky SCID, and combined immune deficiency with granulomas 
or autoimmunity (CID-G/AI). Using next generation sequencing, we analyzed the T and B cell 
receptor (TCR, BCR) repertoire in 12 patients with RAG mutations presenting with Omenn 
syndrome (n=5), leaky SCID (n=3), or CID-G/AI (n=4). Restriction of repertoire diversity skewed 
usage of Variable (V), Diversity (D), and Joining (J) segment genes, and abnormalities of CDR3 
length distribution were progressively more prominent in patients with a more severe phenotype. 
Skewed usage of V,D and J segment genes was present also within unique sequences, indicating a 
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primary restriction of repertoire. Patients with Omenn syndrome had a high proportion of class-
switched immunoglobulin heavy chain transcripts and increased somatic hypermutation rate, 
suggesting in vivo activation of these B cells. These data provide a framework for better 
understanding the phenotypic heterogeneity of RAG deficiency.
Introduction
The RAG1 and RAG2 proteins are expressed in developing lymphocytes and play a critical 
role in the assembly of interspersed Variable (V), Diversity (D), and Joining (J) gene 
elements at the immunoglobulin (Ig) and T cell receptor (TCR) loci, thereby initiating the 
VDJ recombination process that allows development of B and T cells and the establishment 
of adaptive immunity. Patients with null mutations in the RAG1 or RAG2 genes manifest a 
block in the development of B and T cells, resulting in T− B− severe combined immune 
deficiency (T− B− SCID). However, hypomorphic mutations in the RAG genes may allow 
development of a variable number of B and T cells, associated with various distinct clinical 
and immunological phenotypes. In particular, Omenn syndrome (OS) is characterized by 
generalized skin rash, lymphadenopathy, hepatosplenomegaly, eosinophilia, 
hypogammaglobulinemia but elevated serum IgE, lack of circulating B cells and the 
presence of oligoclonal, activated, autologous T cells (1). Atypical or leaky SCID (LS) is 
characterized by the presence of T (and in some cases, B) cells, with variably affected T cell 
function and without clinical features of OS (2). Another form of LS with expansion of T 
cells expressing the γδ form of the TCR occurs especially in patients with cytomegalovirus 
infection (3, 4). More recently, hypomorphic RAG mutations were identified in patients with 
delayed-onset combined immunodeficiency associated with granulomas and/or 
autoimmunity (CID-G/AI) (5, 6), or in other, more rare, milder and atypical presentations, 
including CD4 lymphopenia (7), common variable immune deficiency (8), selective 
deficiency of anti-polysaccharide antibody responses (9), and pyoderma gangrenosum (10). 
These heterogeneous clinical phenotypes are associated with a broad spectrum of nonsense, 
frameshift, in-frame deletion or insertion, and missense mutations of the RAG1 and RAG2 
genes that affect various domains of the respective proteins (11).
By individually introducing a large number of human RAG1 and RAG2 genetic variants into 
Abelson virus-transformed Rag1−/− (or Rag2−/−) pro-B cells carrying an inverted GFP 
cassette flanked by recombination signal sequences (RSS), we previously demonstrated that 
the severity of the clinical presentation correlates with the level of residual recombination 
activity supported by the mutant RAG1 protein (12, 13). In this assay, mutations with low 
levels of recombination activity generated fewer rearrangements at the endogenous 
immunoglobulin heavy chain (Ighc) locus, as compared to mutations with higher residual 
activity (12), suggesting that individual RAG mutations may exert different effects on 
immune repertoire diversity and composition. Here, we report the results of next generation 
sequencing (NGS) of T and B cell repertoire composition and diversity in 12 patients with 
RAG mutations, representative of the extended phenotypic spectrum of the disease. Our 
results demonstrate that abnormalities of T and B cell repertoires correlate with the severity 
of the clinical and immunological phenotype, thus further supporting genotype-phenotype 
correlation in this disease. Distinctive signatures of individual V, D, and J gene usage, and of 
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CDR3 composition and length distribution have been identified in patients with different 
phenotypes, and may contribute to the generation of an immune repertoire enriched in self-
reactive specificities.
Results
Patient Characteristics
The 12 patients included in this study were assigned to three distinct groups, based on the 
clinical and immunological phenotype (2) (Table S1). Five patients (OS1-OS5) presented 
with clinical and laboratory features of OS. Three patients (LS1-LS3) presented with LS and 
severe CMV infection, and two of them had an increased proportion of TCRγδ+ T cells 
(γδT). Four patients (CID1-CID4) were included in the CID-G/AI group based on a clinical 
history of autoimmunity and/or presence of granulomas. Eleven patients carried RAG1 and 
one patient carried RAG2 bi-allelic mutations, for a total of fifteen RAG1 and one RAG2 
distinct mutant alleles. Recombination activity of the mutant alleles was tested using 
Abelson virusimmortalized Rag1−/− or Rag2−/− pro-B cells as previously described (12, 13). 
Patients in the OS and LS subgroups carried RAG mutant alleles that supported only modest 
levels of recombination activity (<7% of wild-type, with a mean of 2.29%). By contrast, 
patients in the CID-G/AI group carried at least on one RAG mutant allele that conferred 
higher levels of recombination activity (Table S2).
Progressive restriction of the immune repertoire correlates with the severity of the clinical 
phenotype
To analyze and compare IGH and TRB repertoire diversity in patients with various clinical 
phenotypes associated with RAG mutations (Fig. 1A and Table S1), we have performed 
NGS of the IGH and TRB transcripts expressed by circulating B and T cells, respectively. 
The number of total and unique sequences of rearranged IGH and TRB products for each of 
the RAG-deficient patients and healthy infant controls is reported in Table S2. Of note, 
productive IGH rearrangements were detected in 3 out of five OS patients, despite virtual 
lack of circulating B cells. A lower ratio of unique/total IGH and TRB sequences was 
detected in RAG-mutated patients vs. healthy controls (Table S2), and this difference 
reached statistical significance for the IGH repertoire (p<0.05).
A graphical representation of repertoire diversity is conveyed by tree maps of the IGH and 
TRB (Fig. 1B) repertoires, where each dot represents a unique V-J pair and the size of each 
dot corresponds to the frequency of that rearrangement in the total population of sequences 
obtained. Marked reduction of both TRB and IGH repertoire diversity, associated with 
clonotypic expansions, was detected in samples from OS patients, and to a lesser extent in 
patients with LS. By contrast, a more diversified IGH repertoire was present in samples from 
the CID-G/AI group. However, the TRB repertoire of CID-G/AI patients was characterized 
by restrictions and clonotypic expansions.
To provide more quantitative measures of repertoire diversity and complexity, we took 
advantage of commonly used ecological parameters. In particular, the Shannon’s H index 
measures repertoire diversity, taking into account both the number of total sequences and 
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clonal size distribution in the overall repertoire. As compared to healthy donors, RAG-
deficient patients had a lower Shannon’s H index for both IGH (Fig. 1C) and TRB (Fig. 1D) 
repertoires. When the same analysis was applied to each of the three subgroups of patients 
with RAG deficiency (CID-G/AI, LS, and OS), a significant reduction of the Shannon’s H 
index was observed only for the IGH repertoire in OS patients (fig. S1, A and B). Next, to 
assess more precisely clonal size distribution, we calculated the Gini-Simpson index of 
unevenness, which measures the inequality in the relative representation of species observed 
in a given sample, so that the higher the Gini Simpson index, the more unequal the 
distribution of individual clonotypes. An uneven distribution of both IGH and TRB 
clonotypes was observed in RAG-deficient patients vs. controls (Fig. 1, E and F). This 
difference was statistically significant for OS patients, but a clear trend was observed for the 
TRB repertoire of CID-G/AI and LS patients (fig. S1, C and D).
To analyze further the presence of clonotypic expansions, we estimated the diversity 50 
(D50) index (14), which corresponds to the percentage of unique CDR3 sequences that 
account for 50% of the total number of sequences observed. Less than 10% of the unique 
clonotypes accounted for 50% of the total number of IGH sequences in patients with OS 
(Fig. 1G). Clonotypic expansions, resulting in markedly reduced D50, were observed in the 
TRB of all RAG-mutated patients, irrespective of their clinical phenotype (Fig. 1H). The top 
100 most abundant IGH and TRB CDR3 (CDR-H3, CDR-B3) clonotypes accounted for less 
than 0.3% of all transcripts in healthy donors. With the exception of a single clonotype in 
patient CID3, all patients with CID-G/AI showed a similar representation of CDR-H3 
clonality, whereas a significant expansion of CDR-H3 clonotypes was detected in patients 
with OS and in patient LS3 (Fig. 1I). A different pattern was observed for the top 100 CDR-
B3 clonotypes. In particular, two CDR-B3 clonotypes accounted for more than 50% of all 
total sequences in patient OS4, and a significant expansion of CDR-B3 clonotypes was also 
observed in patients with CID and LS (Fig. 1J). Overall, these data demonstrate that 
restriction and clonotypic expansions characterize both the TRB and the IGH repertoires of 
patients with OS, whereas in patients with CID-G/AI and LS abnormalities of repertoire 
diversity are comparatively subtle and largely confined to T cells.
Finally, to assess whether analysis of the T and B cell repertoire may distinguish RAG-
deficient patients from healthy controls, we used Principal Component Analysis (PCA) 
based on five variables: the number of total and unique sequences, Shannon’s H index, Gini-
Simpson index, and recombination activity of the mutant RAG protein. PCA successfully 
segregated healthy donors from the patients (Fig. 1, K and L), and permitted discrimination 
amongst different groups (CID-G/AI, LS and OS) of RAG-deficient patients, especially with 
respect to the IGH repertoire (Fig. 1K).
Non-stochastic restriction of IGH and TRB repertoires and skewed usage of V, D, and J 
genes in RAG-mutated patients
The analysis of repertoire diversity and composition among unique and total sequences 
permits distinguishing between constraints that occur during generation of the primary 
repertoire vs. secondary effects that occur in the periphery, such as clonotypic expansions in 
response to non-self or self-antigens. To determine whether RAG mutations alter targeting of 
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individual V, D, and J genes, we generated heat maps comparing usage of these genes in 
unique IGH (Fig. 2A) and TRB (Fig. 2B) sequences from healthy controls and patients. In 
these panels, coding genes are ordered according to their location along the chromosome, 
making it possible to ascertain whether skewed gene usage could reflect topological 
constraints. The summary for the Chi-squared test for goodness of fit shows that in most 
RAG-mutated patients the distribution of V, D and J gene usage among unique IGH and 
TRB sequences was distinct from that observed in healthy controls (Fig. 2, A and B). 
Results were similar when the same analysis was applied to total sequences (fig. S2, A and 
B).
The frequency of individual V, D, and J gene usage among unique sequences of the IGH 
repertoire was different in healthy controls and RAG-mutated patients (Fig. 2C, upper 
panel). For example, the IGHJ3 gene was the second most frequently utilized IGHJ gene in 
patients with RAG deficiency, whereas it was only fourth in order in healthy controls. 
Conversely, IGHJ6 was the second most commonly utilized gene in controls, but was only 
fourth in order in RAG-mutated patients. The IGHD6 gene was the third in frequency among 
healthy controls, but it was the most commonly used in patients LS1 and OS5. Similar 
abnormalities were also observed in the frequency of usage of TRBV, TRBD, and TRBJ 
genes in patients vs. controls (Fig. 2D, upper panel). Moreover, for both IGH and TRB 
repertoires, the distribution of gene usage varied among RAG-mutated patients. The 
observation that such differences were present when analyzing unique sequences suggested 
that hypomorphic RAG mutations may alter selection of genes involved in V(D)J 
recombination during generation of the primary immune repertoire. To test this hypothesis, 
we analyzed the pattern of usage of individual V, D, and J genes at early stages of B and T 
lymphocyte development. In particular, we compared the frequency of IGHV, IGHD, and 
IGHJ gene usage in IGH transcripts from immortalized Rag1−/− pro-B cells engineered to 
express wild-type or mutant human RAG1 (12). As shown in Fig. 2C, lower panel, the 
frequency of usage of individual V, D, and J genes among rearranged IGH products was 
different when comparing cells reconstituted with wild-type or mutant RAG1. To assess 
whether RAG mutations affect composition of T cell repertoire at early stages of T cell 
development, we analyzed the frequency of usage of TRBV, TRBD, and TRBJ genes among 
productive TRB rearrangements during in vitro T cell differentiation of induced pluripotent 
stem cells (15). A different pattern of gene usage was observed in control vs. RAG1 mutant 
cells (Fig. 2D, lower panel). Altogether, these data confirm what observed in vivo in the 
patients (Fig. 2C and 2D, upper panels) and indicate that hypomorphic RAG mutations 
affect not only the efficiency, but also the quality of the V(D)J recombination process.
To further illustrate this, PCA of individual IGHV, D and J gene usage clearly segregated 
patients from controls, and even distinguished among patients with different phenotypes 
(Fig. 2E, left panels). In the variable plot analysis (Fig. 2E, right panels), the distribution of 
the ten most abundantly used IGHV, IGHD, and IGHJ genes along PC1 and PC2 is shown 
for the entire population of subjects analyzed. By overlaying sample and variable plots, it 
was possible to define which genes are preferentially utilized in each subgroup of patients. 
Thus, the T and B cell repertoire of CID-G/AI patients included over-representation of 
IGHV 3-9; IGHD 2-2, 3-9, 4-11, 4-17, 7-27; and, IGHJ3 genes. The IGHJ 1, 2 and 4 genes 
were more abundantly used in patients with OS and LS, and IGHD 2-8 and IGHD6-25 were 
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preferentially used in OS patients. Similarly, PCA segregated the patients from the controls 
based on usage of TRBV, TRBD, and TRBJ genes (Fig. 2F), with clear distinction among 
the various groups of RAG-mutated patients when the analysis was conducted on TRBV and 
TRBJ gene usage. Upon overlaying sample plots with variable plots, patients with CID-G/AI 
were found to have increased usage of TRBJ 1-1, 1-3 and 1-5, whereas overutilization of 
TRBV5-8, 11-2, 4-1 and 18 was detected in patients with LS, and preferential usage of 
TRBJ 2-7 was observed in patients with OS. Similar results were obtained when PCA 
analysis of IGH and TRB gene usage was conducted on total sequences (fig. S2, C, D, E and 
F). Altogether, these data demonstrate that usage of individual V, D, and J genes 
distinguishes RAG-mutated patients from controls, with a specific signature of gene 
expression among patients with distinct phenotypes.
Abnormalities of CDR3 length and amino acid composition
Abnormalities of the Complementarity Determining Region 3 (CDR3) of immunoglobulin 
and T cell receptor molecules CDR3 length and composition often have a significant impact 
on the ability to mount effective adaptive immune responses to a wide range of non-self 
antigens, and may also contribute to increased recognition of self antigens in patients with 
autoimmune diseases (16, 17). Analysis of CDR3 length distribution of both unique (Fig. 3, 
A and B) and total (fig. S3, A and B) IGH and TRB transcripts demonstrated progressive 
skewing of the CDR3 length profile from patients with less severe to patients with more 
severe clinical phenotype. In order to better define abnormalities of CDR3 length 
distribution, we calculated the CDR3 complexity score, and measured CDR3 skewness and 
kurtosis (18–20). In particular, the complexity score takes into account the number of major 
peaks of CDR3 length (defined as those with amplitudes of at least 10% of the sum of all 
peak heights), and their height contribution to the sum of all peak heights. Skewness 
measures the asymmetry of CDR3 length distribution above and below the mean. Finally, 
kurtosis measures the amount of events in the central part of the CDR3 distribution as 
opposed to the tails, and therefore defines the degree of peakedness. Significant differences 
in the complexity score, skewness and kurtosis of the CDR-H3 length profiles of IGH 
repertoire were observed for both unique and total sequences from OS patients, whereas the 
CDR-H3 profile of CID-G/AI and LS patients was similar to the profile observed in healthy 
controls (Fig. 3, C, D, and E; fig. S3, C, D, and E). The CDR-H3 length was not 
significantly different in patients vs. controls (Fig. 3F and fig. S3F). No significant 
differences were observed for the TRB repertoire (Fig. 3, G to J; fig. S3, G to J), although 
there was a trend towards reduced kurtosis in all patient groups. Overall, the observation that 
a similar pattern was detected in unique and total sequences from RAG-mutated patients 
further indicates that abnormalities of IGH and TRB repertoires in these patients can be 
predominantly attributed to the effect of RAG mutations in shaping the primary repertoire.
The CDR3 length is determined not only by the length of V, D and J gene sequences that are 
part of it, but also by the addition of palindromic (P) and ‘N’ nucleotides that contribute to 
its junctional diversity. The germline index (GI) can be used to estimate the abundance of P 
and N nucleotides, and is calculated by dividing the number of nucleotides in the CDR3 that 
are encoded by V, D and J genes by the total number of nucleotides contained in the CDR3, 
generating a value between 0 and 1 (21). A GI value of 1 indicates lack of P and N 
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nucleotide addition; thus, the higher the GI, the lower the junctional diversity. With the 
exception of a lower proportion of unique sequences containing P nucleotides in patients 
with OS, no significant differences were observed in P and N nucleotide addition (fig. S4) 
and in GI value (fig. S5, A and B) within IGH and TRB sequences from patients with RAG 
mutations and controls. Furthermore, CDR-B3 sequences from RAG-mutated patients had a 
GI value between 0.8 and 0.85, which is similar to the GI value observed in healthy controls 
in this study (fig. S5A) and in previous reports (21). Finally, when comparing the proportion 
of unique (fig. S5C) and total (fig. S5D) CDR-B3 sequences with a GI=1, there was a trend 
towards a reduced proportion of these among total sequences from patients with RAG 
mutations, irrespective of the disease phenotype. The average hydrophobicity of the amino 
acids within the CDR-H3 loop of circulating B cells forms a Gaussian distribution centering 
on neutrality to mild hydrophilicity (22, 23). In patients with RAG deficiency, skewed usage 
of V, D, and J genes may affect amino acid composition and the hydrophobicity profile of 
the CDR-H3 region, with potentially important consequences for antigen binding. We have 
observed increased usage of IGHJ3 in patients with CID-G/AI (Fig. 2A) and decreased 
usage of IGHJ6 in all of the patients (Fig. 4A). The IGHJ6 gene encodes for five tyrosine 
residues (Y) in the CDR-H3, whereas IGHJ3 and IGHJ5 do not encode for any tyrosine 
residue (Fig. 4B). Indeed, a low content of tyrosine residues was detected in the CDRH3 
region of immunoglobulin transcripts from patients with RAG mutations, reaching statistical 
significance in patients with CID-G/AI (Fig. 4C). This decreased presence of tyrosine 
residues was associated with abnormalities of the hydrophobicity profile of the CDR-H3 
region in seven out of eight RAG-mutated patients, as measured by the normalized Kyte-
Doolittle index of hydrophobicity of unique (Fig. 4D) and total (Fig. 4E) CDR-H3 
sequences, suggesting that enrichment for immunoglobulin transcripts with an altered 
hydrophobicity profile in patients with RAG mutations occurs at the level of primary 
repertoire generation and is not simply due to expansion of selected clonotypes in the 
periphery.
OS is characterized by infiltration of peripheral tissues by activated, possibly self-reactive T 
cells. Recent data have shown that the hydrophobicity of amino acids (aa) at positions 6 and 
7 of the 13 aa-long CDR-B3 promote the development of self-reactive T cells (24). Amino 
acid composition at positions 6 and 7 of the 13 aa-long CDR-B3 was very conserved in 
healthy controls, but not in RAG-mutated patients (Fig. 4F and 4G, upper panels). 
Furthermore, increased usage of hydrophobic amino acids was observed at both positions 6 
and 7 in patient OS2, whereas the CDR-B3 of patient OS4 was enriched for hydrophobic aa 
at position 7 (Fig. 4F and G, lower panels).
Abnormalities of immunoglobulin class switching and somatic hypermutation in patients 
with OS
Abnormalities of T and B cell development in patients with RAG mutations compromise 
immune responses in peripheral lymphoid organs, including production of antibodies of 
various isotypes. In particular, low IgG and low IgA, but elevated IgE serum levels, are 
typically seen in patients with OS, and may be observed also in LS (25). However, virtual 
lack of B cells in patients with OS has so far precluded analysis of the distribution of B cells 
expressing various isotypes in the periphery of these patients. NGS analysis of the B cell 
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repertoire, with use of RNA as a template and reverse primers in the IGHC region, permitted 
analysis of the relative abundance of immunoglobulin transcripts containing various heavy 
chain isotypes in the peripheral blood of patients with RAG mutations and healthy controls. 
Consistent with the notion that unswitched cells comprise the majority of circulating B cells 
in normal individuals, switched transcripts represented less than 5% of all IGH productive 
transcripts detected in healthy controls both within both unique (Fig. 5, A and B) and total 
(fig. S6, A and B) sequences, as also previously reported (26). By contrast, an increased 
frequency of IGHG transcripts was observed within unique and total sequences of CID3, 
LS3, OS1, OS3 and OS5 patients, and increased frequency of IGHE transcripts was 
observed in OS1 and OS3 patients (Fig. 5A and fig. S6). Overall, patients with OS showed 
an increased frequency of IGHG and IGHE transcripts (Fig. 5B and fig. S6B). The most 
abundant CDR-H3 clonotypes accounted for a large proportion of total sequences in patients 
with OS (Fig. 5C), and were mainly represented by IGHE and/or IGHG transcripts (Fig. 
5D). These data suggest that the few circulating B cells in patients with OS are represented 
by oligoclonal populations that have switched to IgE and IgG.
Somatic Hyper Mutation (SHM) introduces additional diversity in the IGH repertoire of 
mature B cells and allows selection of high-affinity antibodies. The SHM rate per 1000 
nucleotides (nt) for all combined isotypes was higher in RAG-deficient patients than in 
controls, and this increase was more pronounced in patients with OS (Fig. 5E). When SHM 
was analyzed separately for the various isotypes, healthy controls showed a lower rate of 
SHM in IGHM transcripts than in switched transcripts, as expected. As compared to healthy 
controls, patients CID1, CID2, LS1 and OS5 had a higher SHM rate among IGHM 
transcripts (Fig. 5E). As for IGHG transcripts, a lower rate of SHM was observed in most of 
the patients compared to controls, with the exception of patients CID2 and OS5 (Fig. 5E). In 
the latter, a higher rate of SHM rate was observed also among IGHE transcripts. To 
determine whether SHM detected in Ig transcripts from patients with RAG deficiency 
reflects in vivo antigen-mediated selection, we have assessed the distribution of replacement 
and silent mutations based on the Lossos multinomial model (27) (fig. S7). A clear evidence 
for antigen-mediated selection was observed in switched transcripts from patients OS3 and 
OS5 (Fig. 5F). Furthermore, both in patients with CID-G/AI and in controls, the rate of 
SHM was slightly increased in the preferentially rearranged IGHV3-9 gene as compared to 
the mean in all other genes, and this phenomenon was associated with clear evidence of 
antigen-mediated selection (Fig. 5G). Overall, these data indicate that despite restriction of 
primary repertoire generation, B cell function in patients with RAG deficiency remains 
intact with respect to CSR and SHM.
Mapping the disease-related mutations onto the synaptic-RAG complex models
Recently, crystallography and cryo-electron microscopy have allowed high resolution 
determination of the RAG1/RAG2 heterotetrameric complex (28, 29). We have mapped the 
twelve missense mutations from our patient cohort onto the cryo-electron microscopy 
structure in complex with synapsed RSS DNAs (28), and compared the predicted structural 
and functional effects (Fig. 6A) with analysis of recombination activity (12). The RAG1 
mutations at positions R396, R404, R737, R841 and R973 resulted in less than 10% 
recombination activity (12). While residues R396, R737 and R973 directly engage in RSS 
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binding using their side chains, residue R841 plays a role in stabilizing the closed 
conformation of the synaptic RAG complex by forming a salt bridge with the symmetric 
RAG1 (28) (Fig. 6B). The RAG1 mutation at position R404 likely affects RSS binding and 
conformation of the nonamer binding domain dimer because it stacks with R443 of the other 
RAG1 monomer (28, 29) (Fig. 6B). In contrast, the RAG1 mutation H612R did not 
compromise the recombination activity (12), likely due to the compensation of RSS binding 
by the mutated arginine (Fig. 6B).
Discussion
In the present study, we have demonstrated that the T and B cell repertoire of patients with 
OS is characterized by markedly reduced diversity, and a non-stochastic restriction of V, D, 
and J gene usage. Restriction of TRB repertoire diversity, with skewed V-J gene usage, in 
OS patients has also been reported by Yu et al. in four patients with OS (21). These data 
suggest that severe RAG mutations may impose constraints during generation of primary T 
and B cell repertoires, and that peripheral expansion in response to self or non-self antigens 
is not the only factor involved in the dominance of few T cell clonotypes.
In contrast to what is known about T and B cell abnormalities in patients with OS, limited 
information is available on the richness and complexity of T and B cell repertoire in patients 
with milder forms of RAG deficiency. Flow cytometric analysis of the expression of various 
TCR Vβ families and CDR3 spectratyping have revealed that patients with CID-G/AI and 
with CD4 lymphopenia often maintain a largely polyclonal T cell repertoire, although in 
some cases underand over-representation of individual TCR Vβ families have been 
documented (5, 7, 30, 31). However, these methods have limitations and do not permit 
analysis of CDR3 composition and use of individual V, D, and J genes. Here, we have shown 
that patients with CID-G/AI have reduced T cell repertoire diversity, with clonotypic 
expansions, and maintain a largely diversified B cell repertoire, with even distribution of 
individual clonotypes, but skewed usage of IGHV, IGHD, and IGHJ genes. We have also 
demonstrated that analysis of repertoire diversity and composition may distinguish not only 
RAG-mutated patients from controls, but correctly identifies patients with distinct clinical 
phenotypes. However, genotype-phenotype correlation in RAG deficiency is not absolute. 
Ijspeert et al. have demonstrated that patients carrying RAG mutations that affect the same 
region in the non-core domain of the RAG1 molecule, and allow similar levels of 
recombination activity, may present with distinct clinical and immunological features, thus 
emphasizing the role played by other genetic and epigenetic factors in determining the 
phenotype (32).
The catalytic core of RAG1 contains two coding flank-sensitive regions, at amino acid (aa) 
609–614 (33) and aa 892–977 (34). Several RAG1 mutations associated with CID-G/AI fall 
within these coding flank-sensitive regions (11, 28), including the p.H612R mutation in 
patient CID1 and the p.F974L mutation in patient CID3. Studies in vitro had suggested that 
missense mutations in the coding flank-sensitive regions of RAG1 may perturb repertoire 
composition not just by affecting DNA cleavage, but also by preferentially targeting some 
coding elements (35). Indeed, patients CID1 and CID3 showed a skewed usage of individual 
V, D, and J genes. In particular, we have demonstrated increased usage of IGHV3-9, 
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IGHV4-31, and IGHV3-23, that are also expressed by autoantibody-secreting B cells in 
patients with tumors (36). These data suggest that perturbation of repertoire composition 
may contribute to the immune dysregulation observed in patients with CID-G/AI.
The length and amino acid composition of the immunoglobulin CDR3 region affect 
recognition of antigens. Progressive reduction of CDR3 length, and increase of highly 
hydrophobic and hydrophilic sequences during differentiation from immature to naïve and 
memory B cells are paralleled by a progressive decrease in the proportion of self-reactive B 
cell specificities during B cell ontogeny (37). We identified abnormalities of hydrophobicity 
profile of the CDR-H3 region in seven out of eight patients with hypomorphic RAG 
mutations, including all three patients with CID-G/AI tested. Close examination of amino 
acid composition revealed decreased frequency of tyrosine residues, which are abundant in 
CDR-H3 sequences of peripheral blood B cells from healthy controls (38). These 
abnormalities reflected markedly decreased usage of the IGHJ6 gene, which encodes for five 
tyrosine residues. Furthermore, we have reported that the CDR-B3 of patients with OS is 
characterized by an increased frequency of hydrophobic amino acids at positions 6 and 7 of 
the CDR-B3, which has been previously associated with promotion of self-reactive T cells 
(24).
The analysis of the distribution of immunoglobulin heavy chain isotypes and somatic 
hypermutation has revealed unexpected features in patients with hypomorphic RAG 
mutations. In particular, we observed that the majority of immunoglobulin heavy chain 
transcripts in patients with OS were represented by switched transcripts, and IgE in 
particular. Direct μ to ε CSR has been previously reported in immature B cells from a mouse 
model with hypomorphic Rag1 mutations (39). We have also demonstrated the presence of 
SHM in Ig transcripts from patients carrying hypomorphic RAG mutations, including 
patients with OS, who have very low to undetectable circulating B cells, disorganized 
secondary lymphoid organs, with lack of follicles and germinal centers, where SHM is 
actively induced (40). Our observation of CSR and SHM in peripheral blood B cells from 
patients with OS is consistent with previous evidence of Blimp1+ CD138+ plasma cells in 
lymph nodes from patients with OS, and with homeostatic expansion of immunoglobulin-
secreting cells and increased expression of Activation-Induced Cytidine Deaminase 
(AICDA), in mouse models of this disease (41, 42).
Although this study offers insights into the mechanisms underlying the immunopathology 
and phenotypic heterogeneity of human RAG deficiency, it has important limitations, 
including the small sample size of each phenotypic subgroup of patients analyzed, and the 
inability to study both T and B cell repertoires in each patient. Despite these limitations we 
have provided a detailed analysis of T and B cell repertoire in patients with hypomorphic 
RAG mutations that are illustrative of the entire phenotypic spectrum of the disease. After 
introduction of newborn screening for SCID and related conditions, RAG mutations have 
emerged as the most common genetic defect associated with OS and atypical SCID (43). 
Detailed analysis of the immune repertoire in RAG-mutated patients may have important 
predictive implications, and may influence therapeutic interventions.
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Material and Methods
Study Design
One to 5 ml of EDTA-blood samples were obtained upon written informed consent from 
patients diagnosed with RAG deficiency and a known clinical and immunological 
phenotype. The study was performed under the approval of the Institutional Review Board 
of Boston Children’s Hospital, Harvard Medical School. For healthy controls, de-identified 
left-over blood samples were used, that had been obtained from children at the age of 9 
months to 4 years at the time of regular well-child visits.
Generation and Analysis of T and B cell receptor repertoire by NGS
Equal amounts of total RNA extracted from peripheral blood of patients with RAG 
deficiency (n=5 for patients with OS; n=3 for patients with LS; and n=4 for patients with 
CID-G/AI) and from peripheral blood of healthy infants (n=3 for TRB and n=4 for IGH; age 
range: 9 months-4 years) were used as template to semi-quantitatively amplify the 
rearrangements at the endogenous T cell receptor beta (TRB) and immunoglobulin heavy 
chain (IGH) loci according to the manufacturer’s protocol (iRepertoire, Inc) (44). PCR 
products were purified and sequenced using the GS Junior 454 platform (Roche, Inc).
Raw sequences were filtered for PCR errors, and resulting FASTA sequences were 
submitted to IMGT HighV-QUEST, and analyzed for V, D, and J gene usage, composition 
and length of the CDR-3, Kyte-Doolittle index of hydrophobicity, SHM and antigen-
mediated selection using the IgAT software (45), as previously described (23). The 
sequences of TRB and IGH transcripts, upon processing through IMGT, are posted in the 
Supplementary Table 3. The diversity indices of Shannon’s H entropy and Gini Simpson’s D 
indexes were calculated using the VDJ statistics file from IgAT analysis and the PAST 
program, as described (23). D50 was calculated by determining the cumulative frequency of 
total sequences that constitute 50% of the cumulative unique sequences frequency (14). D50 
is graphically represented by plotting the cumulative frequency of total sequences on the x-
axis against cumulative frequency of unique sequences on the y-axis and then finding the 
intercept on the y axis of values that correspond to 50% on the×axis. Graphical 
representation of V-J pairing and the relative distribution of distinct rearrangements, 
hierarchical tree maps and isotype usages were generated using the iRepertoire software. All 
raw data used for the analyses represented in the various Figures are posted in 
Supplementary Table 3.
The complexity Score of the CDR3 length distribution was determined based on the 
followingcalculation (46):
where:
N = number of all the sequences studied (either unique or total
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MP = major peak, defined by constituting at least 10% of N
mp = number of all the MP
nMP = number of sequences in each MP
NMPs = number of MP
RAG activity
The activity of various RAG mutant proteins was determined by a flow cytometric-based 
assay as previously described (12, 13), and expressed as percentage of the recombination 
activity of the wild type protein.
Statistical analysis
Unpaired t-test was used to compare the patient blood samples to infant controls for 
variables with normal distribution. For non-parametric variables, the Mann-Whitney test was 
used. The χ2 test was used for categorical values. For all multiple t-tests, post hoc 
Bonferroni correction was applied. ANOVA with Dunnett’s correction for multiple 
comparisons was used when comparing more than two groups. The analyses were performed 
using PRISM version 6 (Graph Pad). Non-hypothesis driven statistical analysis of Principal 
Component Analysis (PCA) was performed using the Excel add-in Multibase package 
(Numerical Dynamics, Japan).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Progressive IGH and TRB repertoire restriction with increased clonality in the patients 
with RAG deficiency
Schematic representation of RAG1 and RAG2 protein with the mutations of the 12 patients 
according to the severity of clinical presentation from top to bottom (A). Tree maps 
representing the diversity and clonality of IGH and TRB (B) repertoires from healthy donor 
controls (representative data from two subjects are presented) and patients with RAG 
mutations. Each dot represents a unique V to J joining, and the size of the dot represents the 
relative frequency of that rearrangement in the entire population. No amplification products 
were obtained for IGH repertoire from patients CID4, LS2, OS2, and OS4, and for TRB 
repertoire for patients CD1, LS1, OS1, OS3, and OS5. Quantification of the diversity (C, D) 
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and unevenness (E, F) of the IGH (C, E) and TRB (D, F) repertoires using Shannon’s H 
index of diversity and Gini- Sipmson’s index of unevenness in healthy controls (blue 
circles), and patients with CID-G/AI (purple boxes), LS (green boxes), and OS (red boxes). 
The cumulative frequencies of unique versus total CDR3 clonotypes are shown for IGH (G) 
and TRB (H) repertoires (CDR-H3 and CDR-B3, respectively). Mean values ± SE are 
shown; t-test was used for statistical analysis. Representation of the frequency of the top 100 
most abundant clones for IGH (I) and TRB (J) sequences in RAG-mutated patients and 
healthy controls (mean ± SE; ANOVA with post hoc test of Dunnett’s multiple comparisons 
with *** 0.001 < p < 0.01 and * p < 0.05). Sample plots illustrating the segregation of the 
various patient groups from healthy controls based on primary component (PC) 1 and 2 
determined by five variables (RAG recombination activity, Shannon’s H, Gini-Simpson, 
number of total and unique sequences) for the IGH (K) and TRB (L) repertoires.
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Fig. 2. Differential usage of V, D and J genes in the IGH and TRB repertoires of patients with 
RAG deficiency
Heat map representing the frequency of V, D and J gene usage among unique IGH (A) and 
TRB (B) sequences from healthy controls and RAG-mutated patients. Relative frequency of 
usage of IGHV and IGHD gene families, and of individual IGHJ genes, in healthy controls 
and in patients (C, upper panel) and in Abelson virus-transformed pro-B cell lines 
expressing various RAG1 mutations (C, lower panel). Relative frequency of usage of TRBV 
gene family and of TRBD and TRBJ genes in healthy controls and in patients (D, upper 
panel) and in iPS-derived thymocytes (D, lower panel). In panel E, differential usage of 
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IGHV, IGHD and IGHJ genes, segregating control and patient samples and the various 
genes according to PC1 and PC2 is shown as sample plots (left panels) and variable plots 
(right panels). In panel F, differential usage of TRBV, TRBD and TRB genes, segregating 
control and patient samples and the various genes according to PC1 and PC2 is shown as 
sample plots (left panels) and variable plots (right panels).
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Fig. 3. Characteristics of the CDR3 region of IGH and TRB unique sequences in peripheral blood 
lymphocytes
Distribution of the length of the CDR3 region of IGH (CDR-H3) (A) and TRB (CDR-B3) 
(B) unique sequences from peripheral blood of patients with RAG deficiency and healthy 
controls (C1-C4; C6-C8). In panels A and B, the distribution of the CDR3 length in healthy 
controls is depicted as a blue line (representing mean values ± SE). Complexity scores (C, 
G), skewness (D, H), kurtosis (E, I) and average length in nucleotides (nt) (F, J) of the IGH 
(C-F) and TRB (G-J) CDR3 unique sequences in patients with RAG deficiency and 
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controls. In panels C-J, for each group, mean values are shown, and statistical significance 
was assessed by ANOVA.
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Fig. 4. Abnormal amino acid composition of CDR3 in the IGH and TRB sequences
Frequency of usage of the IGHJ6 gene among unique CDR-H3 sequences (A). Summary of 
the Y content in the IGHJ genes (B). Percentage of tyrosine residues in the CDR-H3 of 
unique and total sequences (C). Summary of CDR-H3 hydrophobicity profile depicted as 
average Kyte-Doolittle index of hydrophobicity (mean ± SE) in patients and healthy control 
blood samples for unique (D) and total (E) sequences. (**, p<0.01; ***, p <0.001; ****, p < 
0.0001; one-tail unpaired t-test). Amino acid composition of CDR-B3 in patients and 
healthy control for amino acid positions 6 (F) and 7 (G) of the 13 aa-long CDR-B3.
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Fig. 5. Distribution of immunoglobulin heavy chain isotypes, somatic hypermutation and 
antigen-driven selection in peripheral blood B cells of patients with RAG deficiency
Frequency of immunoglobulin heavy chain constant gene usage among unique IGH 
sequences from peripheral blood lymphocytes of RAG-deficient patients and healthy 
controls (A and B). In panel B, mean values ± SE are shown (one-tail, unpaired t-test). 
Contribution of the most abundant clonotype to the total number of IGH sequences in 
patients and controls (C). Distribution of various isotypes among the most abundant IGH 
transcript (D). Rate of somatic hypermutation (SHM) in IGH transcripts (E, mean ± SE; 
unpaired t-test). Frequency of unique IGH transcripts displaying evidence of antigen-
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mediated selection based on the distribution of replacement and silent mutations (F). Rate of 
SHM and antigen mediated selection in IGHV3-9 for patients with CID-G/AI and healthy 
controls with line at the mean (G).
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Fig. 6. Mapping the disease-related mutations onto the synaptic-RAG complex models
Overview of the disease-related mutations shown as space filling models mapped onto the 
ribbon diagram of the synaptic RAG complex structure (PDB ID 3JBY, top and bottom 
view) (A). Residues in zebrafish rag1 and rag2 and the equivalent residues that have been 
mutated in patients are labeled. Only one RAG1-RAG2 subunit is labeled for explicitness on 
the side view. Labeled in purple and red are residues that are mutated in patients with CID-
G/AI and OS, respectively. Residues affected by mutations that correspond to the allele with 
lower recombination activity in compound heterozygous patients are labeled in black. 
Examples of the detailed interactions between the equivalent residues from patients and the 
RSS intermediates or partner residues (PBD ID 3GNA and 3JBY) (B). Equivalent residues 
that have interaction with RSS intermediates are shown as sticks and highlighted in magenta. 
The nucleotides in the RSS intermediates that have interaction with protein residues are 
shown as sticks and highlighted in cyan. The partner residues are shown as sticks and 
highlighted in marine. Potential interactions are displayed as red dashed lines. z is 
abbreviated for zebrafish and m is for mouse. All molecular representations were generated 
in PyMOL (http://www.pymol.org) (47).
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